Comparative Pharmacology
Head-to-head clinical analysis: NATURAL ESTROGENIC SUBSTANCE ESTRONE versus STILBETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NATURAL ESTROGENIC SUBSTANCE ESTRONE versus STILBETIN.
NATURAL ESTROGENIC SUBSTANCE-ESTRONE vs STILBETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrone binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent estrogenic effects on target tissues.
Diethylstilbestrol (STILBETIN) is a nonsteroidal estrogen that binds to estrogen receptors, activating estrogen-responsive genes, leading to increased synthesis of proteins involved in growth and differentiation of female reproductive tissues.
0.1 to 0.5 mg intramuscularly 2 to 3 times per week for estrogen replacement therapy
25 mg orally 3 times daily for 5 days; repeat if necessary after 1 month.
None Documented
None Documented
Terminal half-life: 24-48 hours (prolonged due to enterohepatic recirculation and tissue distribution).
Terminal elimination half-life is approximately 1-2 hours (range 1-3 h) for estradiol; clinical relevance: requires multiple daily dosing (e.g., 3-4 times/day) for sustained effect.
Renal: ~50% (as glucuronide and sulfate conjugates), Biliary/Fecal: ~50% (enterohepatic recirculation).
Primarily renal as glucuronide and sulfate conjugates; approximately 50-80% of a parenteral dose excreted in urine within 24 hours; 10-20% via bile into feces.
Category C
Category C
Estrogen
Estrogen